The administration of scopolamine results in several pathological changes that are characteristic of AD, including the deposition of Aβ, hyperphosphorylation of tau proteins, and increased oxidative stress levels (Chen and Yeong, 2020; Yadang et al., 2020). The gene discussed is MAPT; the disease is Alzheimer disease.